Nasopharyngeal carcinoma: an evolving paradigm.

Humans Nasopharyngeal Carcinoma

Journal

Nature reviews. Clinical oncology
ISSN: 1759-4782
Titre abrégé: Nat Rev Clin Oncol
Pays: England
ID NLM: 101500077

Informations de publication

Date de publication:
11 2021
Historique:
accepted: 18 05 2021
pubmed: 2 7 2021
medline: 18 11 2021
entrez: 1 7 2021
Statut: ppublish

Résumé

The past three decades have borne witness to many advances in the understanding of the molecular biology and treatment of nasopharyngeal carcinoma (NPC), an Epstein-Barr virus (EBV)-associated cancer endemic to southern China, southeast Asia and north Africa. In this Review, we provide a comprehensive, interdisciplinary overview of key research findings regarding NPC pathogenesis, treatment, screening and biomarker development. We describe how technological advances have led to the advent of proton therapy and other contemporary radiotherapy approaches, and emphasize the relentless efforts to identify the optimal sequencing of chemotherapy with radiotherapy through decades of clinical trials. Basic research into the pathogenic role of EBV and the genomic, epigenomic and immune landscape of NPC has laid the foundations of translational research. The latter, in turn, has led to the development of new biomarkers and therapeutic targets and of improved approaches for individualizing immunotherapy and targeted therapies for patients with NPC. We provide historical context to illustrate the effect of these advances on treatment outcomes at present. We describe current preclinical and clinical challenges and controversies in the hope of providing insights for future investigation.

Identifiants

DOI: 10.1038/s41571-021-00524-x PMID: 34194007
pubmed: 34194007
doi: 10.1038/s41571-021-00524-x
pii: 10.1038/s41571-021-00524-x
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

679-695

Informations de copyright

© 2021. Springer Nature Limited.

Références

Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018).
pubmed: 30207593 doi: 10.3322/caac.21492
Ferlay, J. et al. Data visualization tools for exploring the global cancer burden in 2020. Cancer Today https://gco.iarc.fr/today (WHO, International Agency for Research on Cancer, 2018).
Lee, A. W. et al. Changing epidemiology of nasopharyngeal carcinoma in Hong Kong over a 20-year period (1980-99): an encouraging reduction in both incidence and mortality. Int. J. Cancer 103, 680–685 (2003).
pubmed: 12494479 doi: 10.1002/ijc.10894
Yu, M. C. & Yuan, J. M. Epidemiology of nasopharyngeal carcinoma. Semin. Cancer Biol. 12, 421–429 (2002).
pubmed: 12450728 doi: 10.1016/S1044579X02000858
Carioli, G. et al. Global trends in nasopharyngeal cancer mortality since 1970 and predictions for 2020: focus on low-risk areas. Int. J. Cancer 140, 2256–2264 (2017).
pubmed: 28224615 doi: 10.1002/ijc.30660
Wei, K. R. et al. Epidemiological trends of nasopharyngeal carcinoma in China. Asian Pacif. J. Cancer Prev. 11, 29–32 (2010).
Barnes, L., Eveson, J., Reichart, P. & Sidransky, D. World Health Organization Classification of Tumours: Pathology and Genetics of Head and Neck Tumours (IARC Press, 2005).
Marks, J. E., Phillips, J. L. & Menck, H. R. The National Cancer Data Base report on the relationship of race and national origin to the histology of nasopharyngeal carcinoma. Cancer 83, 582–588 (1998).
pubmed: 9690553 doi: 10.1002/(SICI)1097-0142(19980801)83:3<582::AID-CNCR29>3.0.CO;2-R
Wang, H. Y. et al. A new prognostic histopathologic classification of nasopharyngeal carcinoma. Chin. J. Cancer 35, 41 (2016).
pubmed: 27146632 pmcid: 4857443 doi: 10.1186/s40880-016-0103-5
Tsao, S. W. et al. Etiological factors of nasopharyngeal carcinoma. Oral. Oncol. 50, 330–338 (2014).
pubmed: 24630258 doi: 10.1016/j.oraloncology.2014.02.006
Liu, Z. et al. Oral hygiene and risk of nasopharyngeal carcinoma-a population-based case-control study in China. Cancer Epidemiol. Biomark. Prev. 25, 1201–1207 (2016).
doi: 10.1158/1055-9965.EPI-16-0149
Chang, E. T. et al. Active and passive smoking and risk of nasopharyngeal carcinoma: a population-based case-control study in southern china. Am. J. Epidemiol. 185, 1272–1280 (2017).
pubmed: 28459936 pmcid: 5860561 doi: 10.1093/aje/kwx018
Bei, J. X., Jia, W. H. & Zeng, Y. X. Familial and large-scale case-control studies identify genes associated with nasopharyngeal carcinoma. Semin. Cancer Biol. 22, 96–106 (2012).
pubmed: 22313875 doi: 10.1016/j.semcancer.2012.01.012
Lu, S. J. et al. Linkage of a nasopharyngeal carcinoma susceptibility locus to the HLA region. Nature 346, 470–471 (1990).
pubmed: 2377207 doi: 10.1038/346470a0
Xu, M. et al. Genome sequencing analysis identifies Epstein−Barr virus subtypes associated with high risk of nasopharyngeal carcinoma. Nat. Genet. 51, 1131–1136 (2019).
pubmed: 31209392 pmcid: 6610787 doi: 10.1038/s41588-019-0436-5
Young, L. S., Yap, L. F. & Murray, P. G. Epstein−Barr virus: more than 50 years old and still providing surprises. Nat. Rev. Cancer 16, 789–802 (2016).
pubmed: 27687982 doi: 10.1038/nrc.2016.92
Lo, K. W., Chung, G. T. & To, K. F. Deciphering the molecular genetic basis of NPC through molecular, cytogenetic, and epigenetic approaches. Semin. Cancer Biol. 22, 79–86 (2012).
pubmed: 22245473 doi: 10.1016/j.semcancer.2011.12.011
Tsang, C. M., Lui, V. W. Y., Bruce, J. P., Pugh, T. J. & Lo, K. W. Translational genomics of nasopharyngeal cancer. Semin. Cancer Biol. 61, 84–100 (2020).
pubmed: 31521748 doi: 10.1016/j.semcancer.2019.09.006
Tsang, C. M. et al. Cyclin D1 overexpression supports stable EBV infection in nasopharyngeal epithelial cells. Proc. Natl Acad. Sci. USA 109, E3473–E3482 (2012).
pubmed: 23161911 pmcid: 3528537 doi: 10.1073/pnas.1202637109
Chen, Y. P. et al. Nasopharyngeal carcinoma. Lancet 394, 64–80 (2019).
pubmed: 31178151 doi: 10.1016/S0140-6736(19)30956-0
Chung, A. K. et al. Targeted sequencing of cancer-related genes in nasopharyngeal carcinoma identifies mutations in the TGF-β pathway. Cancer Med. 8, 5116–5127 (2019).
pubmed: 31328403 pmcid: 6718742 doi: 10.1002/cam4.2429
Tao, Q. & Chan, A. T. Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev. Mol. Med. 9, 1–24 (2007).
pubmed: 17477889 doi: 10.1017/S1462399407000312
Lo, K. W. et al. Hypermethylation of the p16 gene in nasopharyngeal carcinoma. Cancer Res. 56, 2721–2725 (1996).
pubmed: 8665502
Lo, K. W. et al. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res. 61, 3877–3881 (2001).
pubmed: 11358799
Li, L. et al. Epigenetic inactivation of the CpG demethylase TET1 as a DNA methylation feedback loop in human cancers. Sci. Rep. 6, 26591 (2016).
pubmed: 27225590 pmcid: 4880909 doi: 10.1038/srep26591
Jin, H. et al. Epigenetic silencing of a Ca
pubmed: 17640920 pmcid: 1941473 doi: 10.1073/pnas.0700153104
Dai, W. et al. Whole-exome sequencing identifies MST1R as a genetic susceptibility gene in nasopharyngeal carcinoma. Proc. Natl Acad. Sci. USA 113, 3317–3322 (2016).
pubmed: 26951679 pmcid: 4812767 doi: 10.1073/pnas.1523436113
Li, Y. Y. et al. Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations. Nat. Commun. 8, 14121 (2017).
pubmed: 28098136 pmcid: 5253631 doi: 10.1038/ncomms14121
Lin, D. C. et al. The genomic landscape of nasopharyngeal carcinoma. Nat. Genet. 46, 866–871 (2014).
pubmed: 24952746 doi: 10.1038/ng.3006
Hau, P. M. et al. Targeting Epstein−Barr virus in nasopharyngeal carcinoma. Front. Oncol. 10, 600 (2020).
pubmed: 32528868 pmcid: 7247807 doi: 10.3389/fonc.2020.00600
Lin, W. et al. Establishment and characterization of new tumor xenografts and cancer cell lines from EBV-positive nasopharyngeal carcinoma. Nat. Commun. 9, 4663 (2018).
pubmed: 30405107 pmcid: 6220246 doi: 10.1038/s41467-018-06889-5
Chen, Y. P. Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma. Cell Res. 30, 1024–1042 (2020).
Jin, S. et al. Single-cell transcriptomic analysis defines the interplay between tumor cells, viral infection, and the microenvironment in nasopharyngeal carcinoma. Cell Res. 30, 950–965 (2020).
pubmed: 32901110 doi: 10.1038/s41422-020-00402-8 pmcid: 7784966
Li, L. et al. Characterization of the nasopharyngeal carcinoma methylome identifies aberrant disruption of key signaling pathways and methylated tumor suppressor genes. Epigenomics 7, 155–173 (2015).
pubmed: 25479246 doi: 10.2217/epi.14.79
Chan, K. C. A. et al. Analysis of plasma Epstein−Barr virus DNA to screen for nasopharyngeal cancer. N. Engl. J. Med. 377, 513–522 (2017).
pubmed: 28792880 doi: 10.1056/NEJMoa1701717
Zeng, Y. et al. Prospective studies on nasopharyngeal carcinoma in Epstein−Barr virus IgA/VCA antibody-positive persons in Wuzhou City, China. Int. J. Cancer 36, 545–547 (1985).
pubmed: 4055129 doi: 10.1002/ijc.2910360505
Zong, Y. S. et al. Immunoglobulin A against viral capsid antigen of Epstein−Barr virus and indirect mirror examination of the nasopharynx in the detection of asymptomatic nasopharyngeal carcinoma. Cancer 69, 3–7 (1992).
pubmed: 1309307 doi: 10.1002/1097-0142(19920101)69:1<3::AID-CNCR2820690104>3.0.CO;2-7
Ng, W. T. et al. Outcomes of nasopharyngeal carcinoma screening for high risk family members in Hong Kong. Fam. Cancer 9, 221–228 (2010).
pubmed: 19779847 doi: 10.1007/s10689-009-9296-y
Liu, Z. et al. Two Epstein−Barr virus-related serologic antibody tests in nasopharyngeal carcinoma screening: results from the initial phase of a cluster randomized controlled trial in Southern China. Am. J. Epidemiol. 177, 242–250 (2013).
pubmed: 23255783 doi: 10.1093/aje/kws404
Coghill, A. E. et al. Epstein−Barr virus serology as a potential screening marker for nasopharyngeal carcinoma among high-risk individuals from multiplex families in Taiwan. Cancer Epidemiol. Biomark. Prev. 23, 1213–1219 (2014).
doi: 10.1158/1055-9965.EPI-13-1262
Tay, J. K., Lim, M. Y. & Kanagalingam, J. Screening in nasopharyngeal carcinoma: current strategies and future directions. Curr. Otorhinolaryngol. Rep. 2, 1–7 (2014).
doi: 10.1007/s40136-013-0035-4
Ji, M. F. et al. Incidence and mortality of nasopharyngeal carcinoma: interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern China. Ann. Oncol. 30, 1630–1637 (2019).
pubmed: 31373615 doi: 10.1093/annonc/mdz231
Lo, Y. M. et al. Quantitative analysis of cell-free Epstein−Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res. 59, 1188–1191 (1999).
pubmed: 10096545
Chan, K. C. et al. Early detection of nasopharyngeal carcinoma by plasma Epstein−Barr virus DNA analysis in a surveillance program. Cancer 119, 1838–1844 (2013).
pubmed: 23436393 doi: 10.1002/cncr.28001
Lee, A. W. et al. Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int. J. Radiat. Oncol. Biol. Phys. 61, 1107–1116 (2005).
pubmed: 15752890 doi: 10.1016/j.ijrobp.2004.07.702
Miller, J. A., Le, Q. T., Pinsky, B. A. & Wang, H. Cost-effectiveness of nasopharyngeal carcinoma screening with Epstein−Barr virus polymerase chain reaction or serology in high-incidence populations worldwide. J. Natl Cancer Inst. https://doi.org/10.1093/jnci/djaa198 (2020).
Lam, W. K. J. et al. Sequencing-based counting and size profiling of plasma Epstein−Barr virus DNA enhance population screening of nasopharyngeal carcinoma. Proc. Natl Acad. Sci. USA 115, E5115–E5124 (2018).
pubmed: 29760067 pmcid: 5984543 doi: 10.1073/pnas.1804184115
Lam, W. K. J. et al. Methylation analysis of plasma DNA informs etiologies of Epstein−Barr virus-associated diseases. Nat. Commun. 10, 3256 (2019).
pubmed: 31332191 pmcid: 6646310 doi: 10.1038/s41467-019-11226-5
King, A. D. et al. Complementary roles of MRI and endoscopic examination in the early detection of nasopharyngeal carcinoma. Ann. Oncol. 30, 977–982 (2019).
pubmed: 30912815 doi: 10.1093/annonc/mdz106
King, A. D. et al. Primary nasopharyngeal carcinoma: diagnostic accuracy of MR imaging versus that of endoscopy and endoscopic biopsy. Radiology 258, 531–537 (2011).
pubmed: 21131580 doi: 10.1148/radiol.10101241
King, A. D. et al. Early detection of cancer: evaluation of MR imaging grading systems in patients with suspected nasopharyngeal carcinoma. AJNR Am. J. Neuroradiol. 41, 515–521 (2020).
pubmed: 32184223 pmcid: 7077896 doi: 10.3174/ajnr.A6444
Lam, W. K. J. et al. Sequencing analysis of plasma Epstein−Barr virus DNA reveals nasopharyngeal carcinoma-associated single nucleotide variant profiles. Clin. Chem. 66, 598–605 (2020).
pubmed: 32191318 doi: 10.1093/clinchem/hvaa027
Pan, J. J. et al. Proposal for the 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy. Cancer 122, 546–558 (2016).
pubmed: 26588425 doi: 10.1002/cncr.29795
Chan, A. T. et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J. Natl Cancer Inst. 97, 536–539 (2005).
pubmed: 15812080 doi: 10.1093/jnci/dji084
Blanchard, P. et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol. 16, 645–655 (2015).
pubmed: 25957714 doi: 10.1016/S1470-2045(15)70126-9
Ribassin-Majed, L. et al. What is the best treatment of locally advanced nasopharyngeal carcinoma? An individual patient data network meta-analysis. J. Clin. Oncol. 35, 498–505 (2017).
pubmed: 27918720 doi: 10.1200/JCO.2016.67.4119
Al-Sarraf, M. et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J. Clin. Oncol. 16, 1310–1317 (1998).
pubmed: 9552031 doi: 10.1200/JCO.1998.16.4.1310
Wee, J. et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J. Clin. Oncol. 23, 6730–6738 (2005).
pubmed: 16170180 doi: 10.1200/JCO.2005.16.790
Lee, A. W. et al. A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma. Radiother. Oncol. 98, 15–22 (2011).
pubmed: 20971520 doi: 10.1016/j.radonc.2010.09.023
Chen, Y. et al. Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China. Cancer 119, 2230–2238 (2013).
pubmed: 23576020 doi: 10.1002/cncr.28049
Lee, A. W. et al. Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma. J. Natl Cancer Inst. 102, 1188–1198 (2010).
pubmed: 20634482 doi: 10.1093/jnci/djq258
Lee, A. W. M. et al. A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10-year outcomes for efficacy and toxicity. Cancer 123, 4147–4157 (2017).
pubmed: 28662313 doi: 10.1002/cncr.30850
Lee, A. W. et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J. Clin. Oncol. 23, 6966–6975 (2005).
pubmed: 16192584 doi: 10.1200/JCO.2004.00.7542
Lin, J. C. et al. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J. Clin. Oncol. 21, 631–637 (2003).
pubmed: 12586799 doi: 10.1200/JCO.2003.06.158
Chitapanarux, I. et al. Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: randomised, non-inferiority, open trial. Eur. J. Cancer 43, 1399–1406 (2007).
pubmed: 17467265 doi: 10.1016/j.ejca.2007.03.022
Dechaphunkul, T., Pruegsanusak, K., Sangthawan, D. & Sunpaweravong, P. Concurrent chemoradiotherapy with carboplatin followed by carboplatin and 5-fluorouracil in locally advanced nasopharyngeal carcinoma. Head. Neck Oncol. 3, 30 (2011).
pubmed: 21639934 pmcid: 3123312 doi: 10.1186/1758-3284-3-30
Wu, X. et al. Long-term follow-up of a phase III study comparing radiotherapy with or without weekly oxaliplatin for locoregionally advanced nasopharyngeal carcinoma. Ann. Oncol. 24, 2131–2136 (2013).
pubmed: 23661293 doi: 10.1093/annonc/mdt163
Tang, L. Q. et al. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol. 19, 461–473 (2018).
pubmed: 29501366 doi: 10.1016/S1470-2045(18)30104-9
Loong, H. H. et al. Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Radiother. Oncol. 104, 300–304 (2012).
pubmed: 22300609 doi: 10.1016/j.radonc.2011.12.022
Leung, S. F. et al. Pretherapy quantitative measurement of circulating Epstein−Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. Cancer 98, 288–291 (2003).
pubmed: 12872347 doi: 10.1002/cncr.11496
Min, H. et al. A new staging system for nasopharyngeal carcinoma in China. Int. J. Radiat. Oncol. Biol. Phys. 30, 1037–1042 (1994).
pubmed: 7961009 doi: 10.1016/0360-3016(94)90307-7
Chen, Q. Y. et al. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial. J. Natl Cancer Inst. 103, 1761–1770 (2011).
pubmed: 22056739 doi: 10.1093/jnci/djr432
Li, X. Y. et al. Ten-year outcomes of survival and toxicity for a phase III randomised trial of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma. Eur. J. Cancer 110, 24–31 (2019).
pubmed: 30739837 doi: 10.1016/j.ejca.2018.10.020
Xu, C. et al. Chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma: a systemic review and meta-analysis of 2138 patients. J. Cancer 8, 287–297 (2017).
pubmed: 28243333 pmcid: 5327378 doi: 10.7150/jca.17317
Rossi, A. et al. Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: results of a 4-year multicenter randomized study. J. Clin. Oncol. 6, 1401–1410 (1988).
pubmed: 3047335 doi: 10.1200/JCO.1988.6.9.1401
Kwong, D. L. et al. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. J. Clin. Oncol. 22, 2643–2653 (2004).
pubmed: 15226332 doi: 10.1200/JCO.2004.05.173
Chi, K. H. et al. A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients. Int. J. Radiat. Oncol. Biol. Phys. 52, 1238–1244 (2002).
pubmed: 11955734 doi: 10.1016/S0360-3016(01)02781-X
Kong, F. et al. Assessment of radiotherapy combined with adjuvant chemotherapy in the treatment of patients with advanced nasopharyngeal carcinoma: a prospective study. J. BUON 20, 206–211 (2015).
pubmed: 25778317
Chen, L. et al. Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase 3 multicentre randomised controlled trial. Eur. J. Cancer 75, 150–158 (2017).
pubmed: 28235726 doi: 10.1016/j.ejca.2017.01.002
Chen, Y. L., Chang, M. C. & Cheng, W. F. Metronomic chemotherapy and immunotherapy in cancer treatment. Cancer Lett. 400, 282–292 (2017).
pubmed: 28189534 doi: 10.1016/j.canlet.2017.01.040
Twu, C. W. et al. Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein−Barr virus deoxyribonucleic acid. Int. J. Radiat. Oncol. Biol. Phys. 89, 21–29 (2014).
pubmed: 24725686 doi: 10.1016/j.ijrobp.2014.01.052
Liu, Y. C. et al. Prognostic impact of adjuvant chemotherapy in high-risk nasopharyngeal carcinoma patients. Oral. Oncol. 64, 15–21 (2017).
pubmed: 28024719 doi: 10.1016/j.oraloncology.2016.11.008
Chan, A. T. et al. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 33, 569–577 (1995).
pubmed: 7558945 doi: 10.1016/0360-3016(95)00218-N
Group, I. N. C. S. & Trial, V. I. Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV(> or = N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. Int. J. Radiat. Oncol. Biol. Phys. 35, 463–469 (1996).
doi: 10.1016/S0360-3016(96)80007-1
Chua, D. T. et al. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian-Oceanian Clinical Oncology Association Nasopharynx Cancer Study Group. Cancer 83, 2270–2283 (1998).
pubmed: 9840526 doi: 10.1002/(SICI)1097-0142(19981201)83:11<2270::AID-CNCR6>3.0.CO;2-T
Ma, J. et al. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J. Clin. Oncol. 19, 1350–1357 (2001).
pubmed: 11230478 doi: 10.1200/JCO.2001.19.5.1350
Hareyama, M. et al. A prospective, randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma. Cancer 94, 2217–2223 (2002).
pubmed: 12001120 doi: 10.1002/cncr.10473
Chua, D. T. et al. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. J. Clin. Oncol. 23, 1118–1124 (2005).
pubmed: 15657403 doi: 10.1200/JCO.2005.12.081
Hui, E. P. et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J. Clin. Oncol. 27, 242–249 (2009).
pubmed: 19064973 doi: 10.1200/JCO.2008.18.1545
Fountzilas, G. et al. Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. Ann. Oncol. 23, 427–435 (2012).
pubmed: 21525406 doi: 10.1093/annonc/mdr116
Lee, A. W. M. et al. NPC-0501 trial on the value of changing chemoradiotherapy sequence, replacing 5-fluorouracil with capecitabine, and altering fractionation for patients with advanced nasopharyngeal carcinoma. Cancer 126, 3674–3688 (2020).
pubmed: 32497261 doi: 10.1002/cncr.32972
Kong, L. et al. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locoregionally advanced nasopharyngeal carcinoma: interim results from 2 prospective phase 2 clinical trials. Cancer 119, 4111–4118 (2013).
pubmed: 24037893 doi: 10.1002/cncr.28324
Bae, W. K. et al. Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer. Cancer Chemother. Pharmacol. 65, 589–595 (2010).
pubmed: 19830427 doi: 10.1007/s00280-009-1152-0
Li, W. F. et al. Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: long-term results of phase 3 randomized controlled trial. Int. J. Cancer 145, 295–305 (2019).
pubmed: 30613964 doi: 10.1002/ijc.32099
Sun, Y. et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 17, 1509–1520 (2016).
pubmed: 27686945 doi: 10.1016/S1470-2045(16)30410-7
Frikha, M. et al. A randomized trial of induction docetaxel-cisplatin-5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02). Ann. Oncol. 29, 731–736 (2018).
pubmed: 29236943 doi: 10.1093/annonc/mdx770
Yang, Q. et al. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial. Eur. J. Cancer 119, 87–96 (2019).
pubmed: 31425966 doi: 10.1016/j.ejca.2019.07.007
Cao, S. M. et al. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase III multicentre randomised controlled trial. Eur. J. Cancer 75, 14–23 (2017).
pubmed: 28214653 doi: 10.1016/j.ejca.2016.12.039
Tan, T. et al. Concurrent chemo-radiation with or without induction gemcitabine, carboplatin, and paclitaxel: a randomized, phase 2/3 trial in locally advanced nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 91, 952–960 (2015).
pubmed: 25832687 doi: 10.1016/j.ijrobp.2015.01.002
Hong, R. L. et al. Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study. Ann. Oncol. 29, 1972–1979 (2018).
pubmed: 30016391 doi: 10.1093/annonc/mdy249
Zhang, L. et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet 388, 1883–1892 (2016).
pubmed: 27567279 doi: 10.1016/S0140-6736(16)31388-5
Zhang, Y. et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N. Engl. J. Med. 381, 1124–1135 (2019).
pubmed: 31150573 doi: 10.1056/NEJMoa1905287
Petit, C. et al. Network-meta-analysis of chemotherapy in nasopharyngeal carcinoma (MAC-NPC): an update on 8,221 patients. J. Clin. Oncol. 38, 6523–6523 (2020).
doi: 10.1200/JCO.2020.38.15_suppl.6523
Tan, T. H. et al. Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: a systematic review and meta-analysis. Radiother. Oncol. 129, 10–17 (2018).
pubmed: 29555182 doi: 10.1016/j.radonc.2018.02.027
Chen, Y. P. et al. Induction chemotherapy plus concurrent chemoradiotherapy in endemic nasopharyngeal carcinoma: individual patient data pooled analysis of four randomized trials. Clin. Cancer Res. 24, 1824–1833 (2018).
pubmed: 29431618 doi: 10.1158/1078-0432.CCR-17-2656
Wang, B. C., Xiao, B. Y., Lin, G. H., Wang, C. & Liu, Q. The efficacy and safety of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients: a systematic review and meta-analysis. BMC Cancer 20, 393 (2020).
pubmed: 32375701 pmcid: 7204295 doi: 10.1186/s12885-020-06912-3
Wang, P., Zhang, M., Ke, C. & Cai, C. The efficacy and toxicity of induction chemotherapy plus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a meta-analysis of randomized controlled trials. Medicine 99, e19360 (2020).
pubmed: 32150078 pmcid: 7478529 doi: 10.1097/MD.0000000000019360
Chen, Y. P. et al. Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma: CSCO and ASCO guideline. J. Clin. Oncol. 39, 840–859 (2021).
pubmed: 33405943 doi: 10.1200/JCO.20.03237
Lee, A. W. et al. Potential improvement of tumor control probability by induction chemotherapy for advanced nasopharyngeal carcinoma. Radiother. Oncol. 87, 204–210 (2008).
pubmed: 18329742 doi: 10.1016/j.radonc.2008.02.003
Zhao, C. et al. locoregional control and mild late toxicity after reducing target volumes and radiation doses in patients with locoregionally advanced nasopharyngeal carcinoma treated with induction chemotherapy (ic) followed by concurrent chemoradiotherapy: 10-year results of a phase 2 study. Int. J. Radiat. Oncol. Biol. Phys. 104, 836–844 (2019).
pubmed: 30954521 doi: 10.1016/j.ijrobp.2019.03.043
Lei, Y. et al. A gene-expression predictor for efficacy of induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma. J. Natl Cancer Inst. 113, 471−480 (2020).
Qiang, M. et al. A prognostic predictive system based on deep learning for locoregionally advanced nasopharyngeal carcinoma. J. Natl Cancer Inst. 113, 606−615 (2020).
Leung, S. F. et al. Plasma Epstein−Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J. Clin. Oncol. 24, 5414–5418 (2006).
pubmed: 17135642 doi: 10.1200/JCO.2006.07.7982
Ai, Q. Y. et al. Extranodal extension is a criterion for poor outcome in patients with metastatic nodes from cancer of the nasopharynx. Oral. Oncol. 88, 124–130 (2019).
pubmed: 30616782 doi: 10.1016/j.oraloncology.2018.11.007
Zhang, B. et al. Intensity-modulated radiation therapy versus 2D-RT or 3D-CRT for the treatment of nasopharyngeal carcinoma: a systematic review and meta-analysis. Oral. Oncol. 51, 1041–1046 (2015).
pubmed: 26296274 doi: 10.1016/j.oraloncology.2015.08.005
Teoh, M., Clark, C. H., Wood, K., Whitaker, S. & Nisbet, A. Volumetric modulated arc therapy: a review of current literature and clinical use in practice. Br. J. Radiol. 84, 967–996 (2011).
pubmed: 22011829 pmcid: 3473700 doi: 10.1259/bjr/22373346
Lee, F. K. et al. Dosimetric difference amongst 3 techniques: TomoTherapy, sliding-window intensity-modulated radiotherapy (IMRT), and RapidArc radiotherapy in the treatment of late-stage nasopharyngeal carcinoma (NPC). Med. Dosim. 39, 44–49 (2014).
pubmed: 24321222 doi: 10.1016/j.meddos.2013.09.004
He, L. et al. Toxicity and dosimetric analysis of nasopharyngeal carcinoma patients undergoing radiotherapy with IMRT or VMAT: a regional center’s experience. Oral. Oncol. 109, 104978 (2020).
pubmed: 32861986 doi: 10.1016/j.oraloncology.2020.104978
Akbas, U. et al. Nasopharyngeal carcinoma radiotherapy with hybrid technique. Med. Dosim. 44, 251–257 (2019).
pubmed: 30366620 doi: 10.1016/j.meddos.2018.09.003
Bibault, J. E. et al. Clinical outcomes of several IMRT techniques for patients with head and neck cancer: a propensity score-weighted analysis. Int. J. Radiat. Oncol. Biol. Phys. 99, 929–937 (2017).
pubmed: 28864403 doi: 10.1016/j.ijrobp.2017.06.2456
Moreno, A. C. et al. Intensity modulated proton therapy (IMPT) — the future of IMRT for head and neck cancer. Oral. Oncol. 88, 66–74 (2019).
pubmed: 30616799 doi: 10.1016/j.oraloncology.2018.11.015
Beddok, A. et al. Proton therapy for head and neck squamous cell carcinomas: a review of the physical and clinical challenges. Radiother. Oncol. 147, 30–39 (2020).
pubmed: 32224315 doi: 10.1016/j.radonc.2020.03.006
Lewis, G. D. et al. Intensity-modulated proton therapy for nasopharyngeal carcinoma: decreased radiation dose to normal structures and encouraging clinical outcomes. Head. Neck 38, E1886–E1895 (2016).
pubmed: 26705956 doi: 10.1002/hed.24341
Jiří, K. et al. Proton pencil-beam scanning radiotherapy in the treatment of nasopharyngeal cancer: dosimetric parameters and 2-year results. Eur. Arch. Otorhinolaryngol. 278, 763−769 (2020).
Beddok, A. et al. Efficacy and toxicity of proton with photon radiation for locally advanced nasopharyngeal carcinoma. Acta Oncol. 58, 472–474 (2019).
pubmed: 30669927 doi: 10.1080/0284186X.2018.1543948
Park, S. G. et al. Early clinical outcomes of helical tomotherapy/intensity-modulated proton therapy combination in nasopharynx cancer. Cancer Sci. 110, 2867–2874 (2019).
pubmed: 31237050 pmcid: 6726680 doi: 10.1111/cas.14115
Alterio, D. et al. Mixed-beam approach in locally advanced nasopharyngeal carcinoma: IMRT followed by proton therapy boost versus IMRT-only. Evaluation of toxicity and efficacy. Acta Oncol. 59, 541–548 (2020).
pubmed: 32090645 doi: 10.1080/0284186X.2020.1730001
Xiang, M., Chang, D. T. & Pollom, E. L. Second cancer risk after primary cancer treatment with three-dimensional conformal, intensity-modulated, or proton beam radiation therapy. Cancer 126, 3560–3568 (2020).
pubmed: 32426866 doi: 10.1002/cncr.32938
Akbaba, S. et al. Bimodal radiotherapy with active raster-scanning carbon ion radiotherapy and intensity-modulated radiotherapy in high-risk nasopharyngeal carcinoma results in excellent local control. Cancers 11, 379 (2019).
Leeman, J. E. et al. Proton therapy for head and neck cancer: expanding the therapeutic window. Lancet Oncol. 18, e254–e265 (2017).
pubmed: 28456587 doi: 10.1016/S1470-2045(17)30179-1
Verma, V., Mishra, M. V. & Mehta, M. P. A systematic review of the cost and cost-effectiveness studies of proton radiotherapy. Cancer 122, 1483–1501 (2016).
pubmed: 26828647 doi: 10.1002/cncr.29882
Lee, A., Chow, J. C. H. & Lee, N. Y. Treatment deescalation strategies for nasopharyngeal cancer: a review. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2020.6154 (2020).
Au, K. H. et al. Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: a report of 3328 patients (HKNPCSG 1301 study). Oral. Oncol. 77, 16–21 (2018).
pubmed: 29362121 doi: 10.1016/j.oraloncology.2017.12.004
Sommat, K. et al. Clinical and dosimetric predictors of physician and patient reported xerostomia following intensity modulated radiotherapy for nasopharyngeal cancer — a prospective cohort analysis. Radiother. Oncol. 138, 149–157 (2019).
pubmed: 31265972 doi: 10.1016/j.radonc.2019.05.023
Lan, X. et al. Saliva electrolyte analysis and xerostomia-related quality of life in nasopharyngeal carcinoma patients following intensity-modulated radiation therapy. Radiother. Oncol. 150, 97–103 (2020).
pubmed: 32544605 doi: 10.1016/j.radonc.2020.06.016
Zhang, L. L. et al. Risk assessment of secondary primary malignancies in nasopharyngeal carcinoma: a big-data intelligence platform-based analysis of 6,377 long-term survivors from an endemic area treated with intensity-modulated radiation therapy during 2003-2013. Cancer Res. Treat. 51, 982–991 (2019).
pubmed: 30309219 doi: 10.4143/crt.2018.298
Tseng, M. et al. Emerging radiotherapy technologies and trends in nasopharyngeal cancer. Cancer Commun. 40, 395−405 (2020).
Chow, J. C. H., Au, K. H., Mang, O. W. K., Cheung, K. M. & Ngan, R. K. C. Risk, pattern and survival impact of second primary tumors in patients with nasopharyngeal carcinoma following definitive intensity-modulated radiotherapy. Asia Pac. J. Clin. Oncol. 15, 48–55 (2019).
pubmed: 29932287 doi: 10.1111/ajco.12994
Lee, A. W. et al. International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma. Radiother. Oncol. 126, 25–36 (2018).
pubmed: 29153464 doi: 10.1016/j.radonc.2017.10.032
Brouwer, C. L. et al. CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG oncology and TROG consensus guidelines. Radiother. Oncol. 117, 83–90 (2015).
pubmed: 26277855 doi: 10.1016/j.radonc.2015.07.041
Grégoire, V. et al. Delineation of the neck node levels for head and neck tumors: a 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines. Radiother. Oncol. 110, 172–181 (2014).
pubmed: 24183870 doi: 10.1016/j.radonc.2013.10.010
Lee, A. W. et al. International guideline on dose prioritization and acceptance criteria in radiation therapy planning for nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 105, 567–580 (2019).
pubmed: 31276776 doi: 10.1016/j.ijrobp.2019.06.2540
Mnejja, W. et al. Dosimetric impact on changes in target volumes during intensity-modulated radiotherapy for nasopharyngeal carcinoma. Rep. Pract. Oncol. Radiother. 25, 41–45 (2020).
pubmed: 31889919 doi: 10.1016/j.rpor.2019.12.012
Hu, Y. C. et al. Which nasopharyngeal cancer patients need adaptive radiotherapy? BMC Cancer 18, 1234 (2018).
pubmed: 30526538 pmcid: 6288867 doi: 10.1186/s12885-018-5159-y
Yang, H. et al. Replanning during intensity modulated radiation therapy improved quality of life in patients with nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 85, e47–e54 (2013).
pubmed: 23122981 doi: 10.1016/j.ijrobp.2012.09.033
Nishimura, Y. et al. A phase II study of adaptive two-step intensity-modulated radiation therapy (IMRT) with chemotherapy for loco-regionally advanced nasopharyngeal cancer (JCOG1015). Int. J. Clin. Oncol. 25, 1250–1259 (2020).
pubmed: 32221802 doi: 10.1007/s10147-020-01665-2
Fung, N. T. C., Hung, W. M., Sze, C. K., Lee, M. C. H. & Ng, W. T. Automatic segmentation for adaptive planning in nasopharyngeal carcinoma IMRT: time, geometrical, and dosimetric analysis. Med. Dosim. 45, 60–65 (2020).
pubmed: 31345672 doi: 10.1016/j.meddos.2019.06.002
Lim, J. Y. & Leech, M. Use of auto-segmentation in the delineation of target volumes and organs at risk in head and neck. Acta Oncol. 55, 799–806 (2016).
pubmed: 27248772 doi: 10.3109/0284186X.2016.1173723
Tao, C. J. et al. Multi-subject atlas-based auto-segmentation reduces interobserver variation and improves dosimetric parameter consistency for organs at risk in nasopharyngeal carcinoma: a multi-institution clinical study. Radiother. Oncol. 115, 407–411 (2015).
pubmed: 26025546 doi: 10.1016/j.radonc.2015.05.012
Lin, L. et al. Deep learning for automated contouring of primary tumor volumes by MRI for nasopharyngeal carcinoma. Radiology 291, 677–686 (2019).
pubmed: 30912722 doi: 10.1148/radiol.2019182012
Lee, A. W., Ma, B. B., Ng, W. T. & Chan, A. T. Management of nasopharyngeal carcinoma: current practice and future perspective. J. Clin. Oncol. 33, 3356–3364 (2015).
pubmed: 26351355 doi: 10.1200/JCO.2015.60.9347
Liu, Y. P. et al. Surgery for isolated regional failure in nasopharyngeal carcinoma after radiation: selective or comprehensive neck dissection. Laryngoscope 129, 387–395 (2019).
pubmed: 30325027 doi: 10.1002/lary.27317
You, R. et al. Salvage endoscopic nasopharyngectomy is superior to intensity-modulated radiation therapy for local recurrence of selected T1-T3 nasopharyngeal carcinoma — a case-matched comparison. Radiother. Oncol. 115, 399–406 (2015).
pubmed: 25987536 doi: 10.1016/j.radonc.2015.04.024
Lee, A. W. M. et al. Management of locally recurrent nasopharyngeal carcinoma. Cancer Treat. Rev. 79, 101890 (2019).
pubmed: 31470314 doi: 10.1016/j.ctrv.2019.101890
Leong, Y. H. et al. Long-term outcomes after reirradiation in nasopharyngeal carcinoma with intensity-modulated radiotherapy: a meta-analysis. Head. Neck 40, 622–631 (2018).
pubmed: 29130584 doi: 10.1002/hed.24993
Ozyigit, G. et al. A retrospective comparison of robotic stereotactic body radiotherapy and three-dimensional conformal radiotherapy for the reirradiation of locally recurrent nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 81, e263–e268 (2011).
pubmed: 21514737 doi: 10.1016/j.ijrobp.2011.02.054
Lin, R. et al. Nasopharyngeal carcinoma: repeat treatment with conformal proton therapy–dose-volume histogram analysis. Radiology 213, 489–494 (1999).
pubmed: 10551231 doi: 10.1148/radiology.213.2.r99nv29489
Phan, J. et al. Reirradiation of head and neck cancers with proton therapy: outcomes and analyses. Int. J. Radiat. Oncol. Biol. Phys. 96, 30–41 (2016).
pubmed: 27325480 doi: 10.1016/j.ijrobp.2016.03.053
Romesser, P. B. et al. Proton beam reirradiation for recurrent head and neck cancer: multi-institutional report on feasibility and early outcomes. Int. J. Radiat. Oncol. Biol. Phys. 95, 386–395 (2016).
pubmed: 27084656 pmcid: 4997784 doi: 10.1016/j.ijrobp.2016.02.036
Dionisi, F. et al. Clinical results of proton therapy reirradiation for recurrent nasopharyngeal carcinoma. Acta Oncol. 58, 1238–1245 (2019).
pubmed: 31155998 doi: 10.1080/0284186X.2019.1622772
Feehan, P. E. et al. Recurrent locally advanced nasopharyngeal carcinoma treated with heavy charged particle irradiation. Int. J. Radiat. Oncol. Biol. Phys. 23, 881–884 (1992).
pubmed: 1618678 doi: 10.1016/0360-3016(92)90663-3
Hu, J. et al. Salvage treatment using carbon ion radiation in patients with locoregionally recurrent nasopharyngeal carcinoma: initial results. Cancer 124, 2427–2437 (2018).
pubmed: 29579324 doi: 10.1002/cncr.31318
Chan, O. S. & Ngan, R. K. Individualized treatment in stage IVC nasopharyngeal carcinoma. Oral. Oncol. 50, 791–797 (2014).
pubmed: 24518920 doi: 10.1016/j.oraloncology.2014.01.004
Zheng, W. et al. Multimodality treatment may improve the survival rate of patients with metastatic nasopharyngeal carcinoma with good performance status. PLoS ONE 11, e0146771 (2016).
pubmed: 26757277 pmcid: 4710536 doi: 10.1371/journal.pone.0146771
Hui, E. P. et al. Lung metastasis alone in nasopharyngeal carcinoma: a relatively favorable prognostic group. A study by the Hong Kong Nasopharyngeal Carcinoma Study Group. Cancer 101, 300–306 (2004).
pubmed: 15241827 doi: 10.1002/cncr.20358
Pan, C. C. et al. Challenges in the modification of the M1 stage of the TNM staging system for nasopharyngeal carcinoma: A study of 1027 cases and review of the literature. Exp. Ther. Med. 4, 334–338 (2012).
pubmed: 23139721 pmcid: 3460246 doi: 10.3892/etm.2012.584
Tian, Y. H. et al. Oligometastases in AJCC stage IVc nasopharyngeal carcinoma: a subset with better overall survival. Head. Neck 38, 1152–1157 (2016).
pubmed: 27220062 doi: 10.1002/hed.24345
Zou, X. et al. Establishment and validation of M1 stage subdivisions for de novo metastatic nasopharyngeal carcinoma to better predict prognosis and guide treatment. Eur. J. Cancer 77, 117–126 (2017).
pubmed: 28391025 doi: 10.1016/j.ejca.2017.02.029
Le, Q. T. et al. Current treatment landscape of nasopharyngeal carcinoma and potential trials evaluating the value of immunotherapy. J. Natl Cancer Inst. 111, 655–663 (2019).
pubmed: 30912808 pmcid: 7962891 doi: 10.1093/jnci/djz044
Sun, X. S. et al. Identifying optimal candidates for local treatment of the primary tumor among patients with de novo metastatic nasopharyngeal carcinoma: a retrospective cohort study based on Epstein−Barr virus DNA level and tumor response to palliative chemotherapy. BMC Cancer 19, 92 (2019).
pubmed: 30665378 pmcid: 6341516 doi: 10.1186/s12885-019-5281-5
Hu, J. et al. Use of radiation therapy in metastatic nasopharyngeal cancer improves survival: a seer analysis. Sci. Rep. 7, 721 (2017).
pubmed: 28389658 pmcid: 5428776 doi: 10.1038/s41598-017-00655-1
Huang, T. et al. Systemic chemotherapy and sequential locoregional radiotherapy in initially metastatic nasopharyngeal carcinoma: retrospective analysis with 821 cases. Head. Neck 42, 1970–1980 (2020).
pubmed: 32154638 doi: 10.1002/hed.26130
You, R. et al. Efficacy and safety of locoregional radiotherapy with chemotherapy vs chemotherapy alone in de novo metastatic nasopharyngeal carcinoma: a multicenter phase 3 randomized clinical trial. JAMA Oncol. 6, 1345−1352 (2020).
Ma, S. X. et al. The efficacy of first-line chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis. Ann. Transl. Med. 6, 201 (2018).
pubmed: 30023364 pmcid: 6035974 doi: 10.21037/atm.2018.05.14
Chan, A. T. et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J. Clin. Oncol. 23, 3568–3576 (2005).
pubmed: 15809453 doi: 10.1200/JCO.2005.02.147
Chua, D. T. et al. Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma. Head. Neck 30, 863–867 (2008).
pubmed: 18213730 doi: 10.1002/hed.20792
Ma, B. et al. A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein−Barr virus DNA as a biomarker of efficacy. Cancer Chemother. Pharmacol. 62, 59–64 (2008).
pubmed: 17762933 doi: 10.1007/s00280-007-0575-8
You, B. et al. A phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma. Am. J. Clin. Oncol. 35, 255–260 (2012).
pubmed: 21358293 doi: 10.1097/COC.0b013e31820dbdcc
Elser, C. et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J. Clin. Oncol. 25, 3766–3773 (2007).
pubmed: 17704426 doi: 10.1200/JCO.2006.10.2871
Lim, W. T. et al. A phase II study of pazopanib in Asian patients with recurrent/metastatic nasopharyngeal carcinoma. Clin. Cancer Res. 17, 5481–5489 (2011).
pubmed: 21712450 doi: 10.1158/1078-0432.CCR-10-3409
Hui, E. P. et al. Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation. Ann. Oncol. 22, 1280–1287 (2011).
pubmed: 21317222 doi: 10.1093/annonc/mdq629
Li, L. et al. Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study. Invest. New Drugs 38, 1847−1853 (2020).
Ma, B. B. et al. Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group (MC1079). Invest. New Drugs 33, 985–991 (2015).
pubmed: 26084990 doi: 10.1007/s10637-015-0264-0
Chan, A. T. et al. Azacitidine induces demethylation of the Epstein−Barr virus genome in tumors. J. Clin. Oncol. 22, 1373–1381 (2004).
pubmed: 15007085 doi: 10.1200/JCO.2004.04.185
Mesia, R. et al. Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma. Eur. J. Cancer 123, 138–145 (2019).
pubmed: 31698327 doi: 10.1016/j.ejca.2019.10.002
Konteatis, Z. et al. Discovery of AG-270, a first-in-class oral MAT2A inhibitor for the treatment of tumors with homozygous MTAP deletion. J. Med. Chem. 64, 4430–4449 (2021).
pubmed: 33829783 doi: 10.1021/acs.jmedchem.0c01895
Zhu, J. et al. Targeting the polycomb repressive complex-2 related proteins with novel combinational strategies for nasopharyngeal carcinoma. Am. J. Cancer Res. 10, 3267–3284 (2020).
pubmed: 33163269 pmcid: 7642668
Hui, E. P. et al. Efficacy, safety, and pharmacokinetics of axitinib in nasopharyngeal carcinoma: a preclinical and phase II correlative study. Clin. Cancer Res. 24, 1030–1037 (2018).
pubmed: 29301831 doi: 10.1158/1078-0432.CCR-17-1667
Chong, W. Q. et al. Integration of antiangiogenic therapy with cisplatin and gemcitabine chemotherapy in patients with nasopharyngeal carcinoma. Clin. Cancer Res. 26, 5320−5328 (2020).
Young, L. S. & Rickinson, A. B. Epstein−Barr virus: 40 years on. Nat. Rev. Cancer 4, 757–768 (2004).
pubmed: 15510157 doi: 10.1038/nrc1452
Zheng, H. et al. Whole-exome sequencing identifies multiple loss-of-function mutations of NF-κB pathway regulators in nasopharyngeal carcinoma. Proc. Natl Acad. Sci. USA 113, 11283–11288 (2016).
pubmed: 27647909 pmcid: 5056105 doi: 10.1073/pnas.1607606113
Chen, T. C. et al. The immunologic advantage of recurrent nasopharyngeal carcinoma from the viewpoint of Galectin-9/Tim-3-related changes in the tumour microenvironment. Sci. Rep. 7, 10349 (2017).
pubmed: 28871094 pmcid: 5583393 doi: 10.1038/s41598-017-10386-y
Walsh, R. J. et al. Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma (NPC). J. Clin. Oncol. 38, 6535–6535 (2020).
doi: 10.1200/JCO.2020.38.15_suppl.6535
Xu, R.-h, Qiu, M.-Z., Zhang, Y., Wei, X.-L. & Hu, C. First-in-human dose-escalation study of anti-EGFR ADC MRG003 in patients with relapsed/refractory solid tumors [abstract]. J. Clin. Oncol. 38, 3550–3550 (2020).
doi: 10.1200/JCO.2020.38.15_suppl.3550
Wei, J. et al. A phase I/II trial of CRISPR-Cas9-mediated PD-1 knockout Epstein−Barr virus cytotoxic lymphocytes (EBV-CTLs) for advanced stage EBV associated malignancies. J. Clin. Oncol. 36, https://doi.org/10.1200/JCO.2018.36.15_suppl.TPS3118 (2018).
Li, Y. et al. Sequential cytokine-induced killer cell immunotherapy enhances the efficacy of the gemcitabine plus cisplatin chemotherapy regimen for metastatic nasopharyngeal carcinoma. PLoS ONE 10, e0130620 (2015).
pubmed: 26098948 pmcid: 4476660 doi: 10.1371/journal.pone.0130620
Comoli, P. et al. Adoptive transfer of allogeneic Epstein−Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma. Ann. Oncol. 15, 113–117 (2004).
pubmed: 14679129 doi: 10.1093/annonc/mdh027
Comoli, P. et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein−Barr virus-targeted cytotoxic T lymphocytes. J. Clin. Oncol. 23, 8942–8949 (2005).
pubmed: 16204009 doi: 10.1200/JCO.2005.02.6195
Straathof, K. C. et al. Treatment of nasopharyngeal carcinoma with Epstein−Barr virus-specific T lymphocytes. Blood 105, 1898–1904 (2005).
pubmed: 15542583 doi: 10.1182/blood-2004-07-2975
Louis, C. U. et al. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J. Immunother. 33, 983–990 (2010).
pubmed: 20948438 pmcid: 2964409 doi: 10.1097/CJI.0b013e3181f3cbf4
Smith, C. et al. Effective treatment of metastatic forms of Epstein−Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy. Cancer Res. 72, 1116–1125 (2012).
pubmed: 22282657 doi: 10.1158/0008-5472.CAN-11-3399
Chia, W. K. et al. Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma. Mol. Ther. 22, 132–139 (2014).
pubmed: 24297049 doi: 10.1038/mt.2013.242
Lutzky, V. P. et al. Cytotoxic T cell adoptive immunotherapy as a treatment for nasopharyngeal carcinoma. Clin. Vaccin. Immunol. 21, 256–259 (2014).
doi: 10.1128/CVI.00121-13
Smith, C. et al. Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: phenotype and effector function of T cells impact on clinical response. Oncoimmunology 6, e1273311 (2017).
pubmed: 28344888 pmcid: 5353921 doi: 10.1080/2162402X.2016.1273311
Huang, J. et al. Epstein−Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma. Cancer 123, 2642–2650 (2017).
pubmed: 28222215 doi: 10.1002/cncr.30541
Hui, E. P. et al. Phase I trial of recombinant modified vaccinia ankara encoding Epstein−Barr viral tumor antigens in nasopharyngeal carcinoma patients. Cancer Res. 73, 1676–1688 (2013).
pubmed: 23348421 pmcid: 6485495 doi: 10.1158/0008-5472.CAN-12-2448
Sinha, D., Smith, C. & Khanna, R. Joining forces: improving clinical response to cellular immunotherapies with small-molecule inhibitors. Trends Mol. Med. 27, 75−90 (2020).
Hsu, C. et al. Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study. J. Clin. Oncol. 35, 4050–4056 (2017).
pubmed: 28837405 doi: 10.1200/JCO.2017.73.3675
Ma, B. B. Y. et al. Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the Mayo Clinic Phase 2 Consortium (NCI-9742). J. Clin. Oncol. 36, 1412–1418 (2018).
pubmed: 29584545 pmcid: 5941615 doi: 10.1200/JCO.2017.77.0388
Wang, F. et al. Recombinant humanized anti-PD-1 monoclonal antibody (JS001) in patients with refractory/metastatic nasopharyngeal carcinoma: interim results of an open-label phase II clinical study. J. Clin. Oncol. 37, 6017–6017 (2019).
doi: 10.1200/JCO.2019.37.15_suppl.6017
Fang, W. et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol. 19, 1338–1350 (2018).
pubmed: 30213452 doi: 10.1016/S1470-2045(18)30495-9
Wang, S. et al. Preliminary results with tislelizumab, an investigational anti-PD-1 antibody, in Chinese patients with nasopharyngeal cancer (NPC). J. Clin. Oncol. 37, 2556–2556 (2019).
doi: 10.1200/JCO.2019.37.15_suppl.2556
Shen, L. et al. Atezolizumab monotherapy in Chinese patients with locally advanced or metastatic solid tumors. Eur. Soc. Med. Oncol. Asia. Singap. Ann. Oncol. 29, 20 (2018).
Wang, F. H. et al. Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02). J. Clin. Oncol. 39, 704–712 (2021).
pubmed: 33492986 doi: 10.1200/JCO.20.02712 pmcid: 8078488
Wang, B. C. et al. The efficacy and safety of PD-1/PD-L1 inhibitors in patients with recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis. Oral. Oncol. 104, 104640 (2020).
pubmed: 32182550 doi: 10.1016/j.oraloncology.2020.104640
Lim, D. et al. Phase II study of spartalizumab (PDR001) vs chemotherapy (CT) in patients with recurrent/metastatic nasopharyngeal cancer (NPC). Cancer Res. 79, CT150 (2019).
doi: 10.1158/1538-7445.AM2019-CT150
Tang, J. et al. Trial watch: the clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors. Nat. Rev. Drug Discov. 17, 854–855 (2018).
pubmed: 30482962 doi: 10.1038/nrd.2018.210
Kao, H. et al. Combination ipilimumab and nivolumab in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC) — updated efficacy and safety analysis of NCT03097939. Ann. Oncol. 31, S1347–S1354 (2020).
doi: 10.1016/j.annonc.2020.10.260
Lam, W. K. J., Chan, K. C. A. & Lo, Y. M. D. Plasma Epstein−Barr virus DNA as an archetypal circulating tumour DNA marker. J. Pathol. 247, 641–649 (2019).
pubmed: 30714167 pmcid: 6594142 doi: 10.1002/path.5249
Ma, B. B. Y. et al. Recent advances in the development of biomarkers and chemoradiotherapeutic approaches for nasopharyngeal carcinoma. Am. Soc. Clin. Oncol. Educ. Book 40, 1–11 (2020).
pubmed: 32191137
Xie, X., Ren, Y., Wang, K. & Yi, B. Molecular prognostic value of circulating epstein-Barr viral DNA in nasopharyngeal carcinoma: a meta-analysis of 27,235 cases in the endemic area of southeast Asia. Genet. Test. Mol. Biomark. 23, 448–459 (2019).
doi: 10.1089/gtmb.2018.0304
Hui, E. P. et al. Integrating postradiotherapy plasma Epstein−Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy. Ann. Oncol. 31, 769−779 (2020).
Guo, R. et al. Proposed modifications and incorporation of plasma Epstein−Barr virus DNA improve the TNM staging system for Epstein−Barr virus-related nasopharyngeal carcinoma. Cancer 125, 79–89 (2019).
pubmed: 30351466 doi: 10.1002/cncr.31741
Lee, V. H. et al. The addition of pretreatment plasma Epstein−Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification. Int. J. Cancer 144, 1713–1722 (2019).
pubmed: 30192385 doi: 10.1002/ijc.31856
Chan, A. T. C. et al. Analysis of plasma Epstein−Barr virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: a randomized controlled trial. J. Clin. Oncol. https://doi.org/10.1200/JCO.2018.77.7847 (2018).
Lv, J. et al. Liquid biopsy tracking during sequential chemo-radiotherapy identifies distinct prognostic phenotypes in nasopharyngeal carcinoma. Nat. Commun. 10, 3941 (2019).
pubmed: 31477699 pmcid: 6718666 doi: 10.1038/s41467-019-11853-y
Fang, W. et al. EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: implications for oncotargeted therapy. Oncotarget 5, 12189–12202 (2014).
pubmed: 25361008 pmcid: 4322961 doi: 10.18632/oncotarget.2608
Lee, V. H. et al. Correlation of PD-L1 expression of tumor cells with survival outcomes after radical intensity-modulated radiation therapy for non-metastatic nasopharyngeal carcinoma. PLoS ONE 11, e0157969 (2016).
pubmed: 27341634 pmcid: 4920427 doi: 10.1371/journal.pone.0157969
Zhu, Q. et al. Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes. Oncoimmunology 6, e1312240 (2017).
pubmed: 28638740 pmcid: 5467992 doi: 10.1080/2162402X.2017.1312240
Zhang, J. et al. Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma. Med. Oncol. 32, 86 (2015).
pubmed: 25702326 doi: 10.1007/s12032-015-0501-6
Zhou, Y. et al. PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load. Sci. Rep. 7, 43627 (2017).
pubmed: 28256540 pmcid: 5335261 doi: 10.1038/srep43627
Cao, Y. et al. Expression and clinical significance of PD-L1 and BRAF expression in nasopharyngeal carcinoma. BMC Cancer 19, 1022 (2019).
pubmed: 31664962 pmcid: 6819586 doi: 10.1186/s12885-019-6276-y
Huang, Z. L. et al. The prognostic significance of PD-L1 and PD-1 expression in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis. Cancer Cell Int. 19, 141 (2019).
pubmed: 31139018 pmcid: 6530183 doi: 10.1186/s12935-019-0863-5
Goodman, A. M. et al. Prevalence of PDL1 amplification and preliminary response to immune checkpoint blockade in solid tumors. JAMA Oncol. 4, 1237–1244 (2018).
pubmed: 29902298 pmcid: 6139049 doi: 10.1001/jamaoncol.2018.1701
Liu, N. et al. Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol. 13, 633–641 (2012).
pubmed: 22560814 doi: 10.1016/S1470-2045(12)70102-X
Jiang, W. et al. Genome-wide identification of a methylation gene panel as a prognostic biomarker in nasopharyngeal carcinoma. Mol. Cancer Ther. 14, 2864–2873 (2015).
pubmed: 26443805 doi: 10.1158/1535-7163.MCT-15-0260
Tang, X. R. et al. Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study. Lancet Oncol. 19, 382–393 (2018).
pubmed: 29428165 doi: 10.1016/S1470-2045(18)30080-9
Wang, Y. Q. et al. Development and validation of an immune checkpoint-based signature to predict prognosis in nasopharyngeal carcinoma using computational pathology analysis. J. Immunother. Cancer 7, 298 (2019).
pubmed: 31722750 pmcid: 6854706 doi: 10.1186/s40425-019-0752-4
Yang, M. & Huang, W. Circular RNAs in nasopharyngeal carcinoma. Clin. Chim. Acta 508, 240–248 (2020).
pubmed: 32417214 doi: 10.1016/j.cca.2020.05.029
Bruce, J. P. et al. Identification of a microRNA signature associated with risk of distant metastasis in nasopharyngeal carcinoma. Oncotarget 6, 4537–4550 (2015).
pubmed: 25738365 pmcid: 4414210 doi: 10.18632/oncotarget.3005
Li, Q. et al. Prognostic value of maximum standard uptake value, metabolic tumor volume, and total lesion glycolysis of positron emission tomography/computed tomography in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis. Medicine 96, e8084 (2017).
pubmed: 28906411 pmcid: 5604680 doi: 10.1097/MD.0000000000008084
Ma, B. et al. Prospective evaluation of plasma Epstein−Barr virus DNA clearance and fluorodeoxyglucose positron emission scan in assessing early response to chemotherapy in patients with advanced or recurrent nasopharyngeal carcinoma. Br. J. Cancer 118, 1051–1055 (2018).
pubmed: 29555989 pmcid: 5931094 doi: 10.1038/s41416-018-0026-9
Zhang, Y. et al. Prognostic value of the primary lesion apparent diffusion coefficient (ADC) in nasopharyngeal carcinoma: a retrospective study of 541 cases. Sci. Rep. 5, 12242 (2015).
pubmed: 26184509 pmcid: 4505330 doi: 10.1038/srep12242
Hong, J. et al. Value of magnetic resonance diffusion-weighted imaging for the prediction of radiosensitivity in nasopharyngeal carcinoma. Otolaryngol. Head Neck Surg. 149, 707–713 (2013).
pubmed: 23884282 doi: 10.1177/0194599813496537
Qamar, S. et al. Pre-treatment intravoxel incoherent motion diffusion-weighted imaging predicts treatment outcome in nasopharyngeal carcinoma. Eur. J. Radiol. 129, 109127 (2020).
pubmed: 32563165 doi: 10.1016/j.ejrad.2020.109127
Qin, Y. et al. Prognostic value of the pretreatment primary lesion quantitative dynamic contrast-enhanced magnetic resonance imaging for nasopharyngeal carcinoma. Acad. Radiol. 26, 1473–1482 (2019).
pubmed: 30772137 doi: 10.1016/j.acra.2019.01.021
Qamar, S. et al. Pre-treatment amide proton transfer imaging predicts treatment outcome in nasopharyngeal carcinoma. Eur. Radiol. 30, 6339–6347 (2020).
pubmed: 32588210 doi: 10.1007/s00330-020-06985-5
Ai, Q. Y. et al. Prediction of distant metastases from nasopharyngeal carcinoma: Improved diagnostic performance of MRI using nodal volume in N1 and N2 stage disease. Oral. Oncol. 69, 74–79 (2017).
pubmed: 28559024 doi: 10.1016/j.oraloncology.2017.04.008
Bossi, P. et al. Nasopharyngeal carcinoma: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 32, 452−465 (2020).
Luo, X. et al. DNMT1 mediates metabolic reprogramming induced by Epstein−Barr virus latent membrane protein 1 and reversed by grifolin in nasopharyngeal carcinoma. Cell Death Dis. 9, 619 (2018).
pubmed: 29795311 pmcid: 5966399 doi: 10.1038/s41419-018-0662-2
Tsai, C. L. et al. Activation of DNA methyltransferase 1 by EBV LMP1 involves c-Jun NH(2)-terminal kinase signaling. Cancer Res. 66, 11668–11676 (2006).
pubmed: 17178861 doi: 10.1158/0008-5472.CAN-06-2194
Shi, F. et al. Wild-type IDH2 contributes to Epstein−Barr virus-dependent metabolic alterations and tumorigenesis. Mol. Metab. 36, 100966 (2020).
pubmed: 32224436 pmcid: 7109632 doi: 10.1016/j.molmet.2020.02.009
Alajez, N. M. et al. Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98. Cell Death Dis. 1, e85 (2010).
pubmed: 21368858 pmcid: 3035896 doi: 10.1038/cddis.2010.64
Tong, Z. T. et al. EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin. Oncogene 31, 583–594 (2012).
pubmed: 21685935 doi: 10.1038/onc.2011.254
Shu, X. S. et al. FEZF2, a novel 3p14 tumor suppressor gene, represses oncogene EZH2 and MDM2 expression and is frequently methylated in nasopharyngeal carcinoma. Carcinogenesis 34, 1984–1993 (2013).
pubmed: 23677067 doi: 10.1093/carcin/bgt165
Song, L. B. et al. The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J. Clin. Invest. 119, 3626–3636 (2009).
pubmed: 19884659 pmcid: 2786794 doi: 10.1172/JCI39374
Yip, Y. L. et al. Expression of Epstein−Barr virus-encoded LMP1 and hTERT extends the life span and immortalizes primary cultures of nasopharyngeal epithelial cells. J. Med. Virol. 82, 1711–1723 (2010).
pubmed: 20827769 doi: 10.1002/jmv.21875
Liu, H. et al. Promoter methylation inhibits BRD7 expression in human nasopharyngeal carcinoma cells. BMC Cancer 8, 253 (2008).
pubmed: 18778484 pmcid: 2543047 doi: 10.1186/1471-2407-8-253
Shu, X. S. et al. The epigenetic modifier PRDM5 functions as a tumor suppressor through modulating WNT/β-catenin signaling and is frequently silenced in multiple tumors. PLoS ONE 6, e27346 (2011).
pubmed: 22087297 pmcid: 3210799 doi: 10.1371/journal.pone.0027346
He, X. et al. Chromatin remodeling factor LSH drives cancer progression by suppressing the activity of fumarate hydratase. Cancer Res. 76, 5743–5755 (2016).
pubmed: 27302170 pmcid: 7821962 doi: 10.1158/0008-5472.CAN-16-0268

Auteurs

Kenneth C W Wong (KCW)

State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR.

Edwin P Hui (EP)

State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR.

Kwok-Wai Lo (KW)

Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR.
ORCID: 0000-0002-3488-6124

Wai Kei Jacky Lam (WKJ)

Department of Chemical Pathology, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR.
ORCID: 0000-0001-8922-5609

David Johnson (D)

State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR.

Lili Li (L)

State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR.

Qian Tao (Q)

State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR.
ORCID: 0000-0001-5383-4808

Kwan Chee Allen Chan (KCA)

Department of Chemical Pathology, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR.

Ka-Fai To (KF)

Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR.

Ann D King (AD)

Department of Diagnostic Imaging and Interventional Radiology, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR.

Brigette B Y Ma (BBY)

State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR. brigette@clo.cuhk.edu.hk.
ORCID: 0000-0003-4802-1102

Anthony T C Chan (ATC)

State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR. anthony@clo.cuhk.edu.hk.
ORCID: 0000-0002-6912-8091

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Nasopharyngeal carcinoma: an evolving paradigm.
questionsmedicales.fr › Maladies oto-rhino-laryngologiques › Maladies du pharynx › Tumeurs du pharynx › Tumeurs du rhinopharynx › Cancer du nasopharynx › Nasopharyngeal carcinoma: an evolving paradigm.